Aim: To assess the preventive effect on preterm birth of intravaginal ulinastatin (urinary trypsin inhibitor; UTI) administration during the mid-trimester in women with singleton pregnancy and both cervical shortening and lower genital infections. Methods: Pregnant women with a short cervical length < 25 mm between 16 and 26 weeks of gestation and who had been diagnosed with a lower genital infection were randomly assigned for intravaginal UTI administration or placebo. All of the women were screened for infection or inflammation of the lower genital tract, and women with negative results were excluded. Results: Of the 92 patients with a short cervical length who were assessed for eligibility for this study, 86 singleton patients were enrolled. All patients were randomized to one of two treatment groups: patients administered UTI (n = 35) and placebo (n = 35). There were no differences between the two groups in the incidence of preterm delivery before 28, 30, 32, 34 and 37 weeks of gestation and in perinatal outcomes. Conclusion: For women diagnosed with a short cervical length < 25 mm) between 16 and 26 weeks of gestation and lower genital infection, who were at risk of preterm birth, administration of transvaginal UTI with vaginal irrigation showed no apparent benefit. Future research on the efficacy of UTI should evaluate modified modes of UTI application.
Introduction
Preterm birth is a major cause of perinatal morbidity and mortality. A short cervical length on transvaginal ultrasound examination in the mid-trimester is one of the best predictors of preterm birth. [1] [2] [3] [4] [5] When cervical shortening is diagnosed, cervical cerclage has been proposed to prevent preterm birth, [6] [7] [8] although several randomized trials have not supported this practice. [9] [10] [11] As inflammation plays a central role in the pathology of preterm delivery, suppressing such inflammation as cervicitis and chorioamnionitis is crucial for treating preterm delivery. However, Mg sulfate and beta-2 agonists, which are currently used to treat threatened preterm delivery by inhibiting uterine contractions, do not reduce inflammatory response. As a result, Mg sulfate and beta-2 agonist therapies are considered to only treat the symptoms of cervicitis and chorioamnionitis. The use of antibiotic and anti-inflammatory therapies to treat cervicitis and chorioamnionitis has been recently reported. 12, 13 Sakai et al. observed that preterm delivery was more likely in women with a short cervix and increased levels of IL-8 in the cervical mucus when using IL-8 as a marker for cervical inflammation. 14 They also reported that cerclage treatment increased preterm delivery rates when administered to patients with cervical inflammation.
To date, it has not been demonstrated that current treatments for cervicitis and chorioamnionitis decreased inflammatory substances or eradicated pathogenic microbes. Consequently, opinions on the effectiveness of antibiotic therapy remain divided. [15] [16] [17] Microbes associated with cervicitis and chorioamnionitis are not always susceptible to antibiotics. Furthermore, there has been an increase in the incidence of antibiotic-resistant strains. Cervicitis and chorioamnionitis do not always occur as a result of bacterial infections and, therefore, are not considered to be infectious diseases. Inflammatory substances produced by clots and bleeding from stretching and irritation of tissues and uterine cervical erosion may release neutrophils, inducing inflammation. In particular, extravascular blood can cause inflammation. Antibiotics have been shown to be ineffective for inflammation that does not depend on microbes, such as chorioamnionitis. Consequently, due to these limitations in antibiotic therapy, interest in anti-inflammatory treatments for preterm delivery is growing.
One such anti-inflammatory agent is the cyclooxygenase (COX) inhibitor, represented by indomethacin. COX inhibitors have been shown to inhibit the arachidonate cascade, directly inhibiting the production of cytokines, active oxygen and inflammatory proteases. 18 However, as COX inhibitors cause adverse effects on the fetus, including fetal ductus arteriosis closure and reduced fetal renal blood flow, they are only used in emergencies.
The safety of the fetus is an essential consideration before using drugs to prevent preterm delivery. From this perspective, the urinary trypsin inhibitor (ulinastatin; UTI) has attracted attention. UTI, a protease inhibitor that is refined from human urine, has been used clinically to treat shock and acute pancreatitis. 19 Studies of UTI concentrations in various types of urine showed that concentrations were relatively higher in fetal urine and decreased in nursing infants and adult urine. Fetal urine contains almost 50 times the concentration of UTI found in adult urine. 20, 21 Given this quantitative relationship, it has been inferred that UTI plays a major role in the amniotic fluid. 22 The primary mode of action of UTI is through proteases, such as interleukin-1 and interleukin-8. It has recently been reported that UTI has other physiological activity. Preterm delivery was significantly suppressed following the intravaginal administration of UTI in a mouse model of preterm delivery, created by injecting mice with lipopolysaccharide (LPS) in mid-pregnancy. A randomized controlled trial (RCT) of UTI vaginal suppository therapy or ritodrine drip infusion therapy showed that UTI positively impacted reoccurrence of uterine contractions and pregnancy maintenance. 20, 22 Furthermore, UTI was effective in treating threatened preterm delivery in patients with advanced cervical dilation (cervical maturation). 23 As the maturation of the cervix is caused by a cervical inflammatory response, a consideration has been made that UTI could be effective against threatened preterm delivery with cervical inflammation or infection. However, to date, no studies have examined the long-term administration of anti-inflammatory drugs in patients with subclinical infection and inflammation. Although the use of COX inhibitors to treat women with threatened preterm delivery has been reported, treatment was limited to short-term administration due to the possibility of closure of the ductus arteriosus as an adverse drug reaction (ADR). Thus, there is demand for an antiinflammatory that can be well tolerated by the fetus. UTI is believed to be effective for treating cervicitis and chorioamnionitis by inhibiting inflammatory mediators, including inflammatory cytokines, which are a component of the fetus. Therefore, the present multicenter RCT was conducted with the aim of providing evidence for the use topical UTI therapy to prevent high-risk preterm delivery in patients with an infection or inflammation.
Materials and Methods

Study design and setting
The planning and execution of this multicenter RCT were supported and approved by 
Ethical considerations
Before beginning the study, a summary of the research protocol was explained to each patient. It was also explained that no disadvantage was associated with nonparticipation in this research and that participation could be discontinued at any time. The participants were assured that, at any stage in which a clear statistical difference in the incidence rate of preterm delivery would appear in any group, the group in which rates of preterm delivery were clearly higher would have that protocol discontinued. Patients were enrolled and assigned to treatment by each test center participating in this study using an Internet webpage specifically designated for this research. Multiple layers of password protection were established to maximize protection against the leakage of personal information.
Study participants
All women were routinely offered an ultrasound examination between 8 and 11 weeks, 6 days of gestation for pregnancy dating and the early diagnosis of major fetal defects and abnormalities. As part of this study, all patients between 16 and 26 weeks of gestation underwent a transvaginal ultrasound scan to measure cervical length in order to screen for the risk of spontaneous preterm birth. The specifics of the ultrasound evaluation used in this study have been previously described. 5 Briefly, the cervical length was measured along a closed endocervical canal at each visit between 16 and 26 gestational weeks. Pressure on the uterine bottom or lower uterine segment was applied for 30 s as a provocative maneuver, and each scan included an evaluation period of at least 3 min to detect spontaneously occurring cervical shortening. The shortest cervical length for each examination that clearly displayed the internal and external cervical os, with equivalent thickness of the anterior and posterior cervix, was recorded as the cervical length, regardless of whether the measurement was obtained with pressure or was the result of spontaneous dynamic shortening. 24 Women with a cervical length of 25 mm or less were invited to participate in the randomized study, as we previously reported. 25 The exclusion criteria were as follows: fetal abnormalities, regular uterine contractions, rupture of membranes, planned cerclage for a clinical diagnosis of cervical insufficiency and clinically significant maternal-fetal complications that would increase the risk of an indicated preterm birth and potentially confound the study outcome. Women with a dilated cervix during screening were also excluded. Women who had cervical cerclage in a prior pregnancy were not excluded.
After written informed consent had been obtained, all women who met the inclusion criteria and wanted to participate in this study were screened for infection or inflammation of the lower genital tract. Vaginal secretions were collected with a sterile swab stick for cultures and for detecting bacterial vaginosis. Bacterial vaginosis was detected using the Fem Exam kit (Cooper Surgical). [26] [27] [28] [29] [30] The Fem Exam kit contains a colorimetric pH indicator and colorimetric amines tests for use in the characterization of a vaginal fluid sample as follows: (i) a pH test that differentiates vaginal fluid pH < pH 4.7 from vaginal fluid pH ≥ 4.7 and (ii) a test that detects alkali volatilizable amines in vaginal fluid. Cervical secretions were also taken for granulocyte elastase assessment. Granulocyte elastase is a biological marker for inflammation. [31] [32] [33] An increased level of granulocyte elastase in cervical secretions was an independent predictive factor of preterm birth. [32] [33] [34] [35] Elastase concentration was measured by using a kit according to the manufacturer's instructions (granulocyte elastase ELISA, Sanwa Kagaku Kenkyusho). Briefly, supernatants were added to a 96-well microtiter plate coated with antibodies (antihuman elastase mouse monoclonal antibody) specific to granulocyte elastase. After incubation, the wells were washed. Peroxidaselabeled antibodies (antihuman elastase sheep polyclonal antibody) were then added. After incubation, the wells were washed. Substrate (H 2 O 2 ) and ophenylenediammonium dichloride were added, and color development was stopped using a H 2 SO 4 solution. The color intensity of the reaction mixture was measured using a photometer. The cut-off value was 1.6 mg/L for granulocyte elastase based on the manufacturer's instructions and the literature. 36 A qualitative positive result for elastase (kit for detection of granulocytic elastase in cervical mucus) was used for the detection of cervicitis. Those women whose secretions were negative and who had granulocyte elastase concentration less than 1.6 mg/L were defined as negative for lower genital tract infection or inflammation and were excluded from the study. We previously reported the results of an RCT on women with a short cervix without lower genital tract infection or inflammation. 25 The present study included women with a vaginal fluid pH ≥ 4.7 or alkali volatilizable amines found to be positive by the Fem Exam kit or a positive elastase result.
The primary end-point, study design and rationale
The primary end-point indicated below will be evaluated in the groups receiving either intravaginal UTI administration or a placebo, following intravaginal flushing using 500 mL of warm saline. The placebo contained saline only. The secondary end-points of 'Percentage of patients using a tocolytic agent' and 'Mean birth weight' were evaluated by exploratory comparison in the group administered UTI versus the group administered placebo.
The women were analyzed based on their gestational age at delivery. There was no reliable database available in Japan that provided information about preterm delivery rates achieved following intravaginal flush with 500 mL of warm saline in patient groups, similar to this study. Therefore, an assumption was made that 10-20% of preterm deliveries occurred at less than 33 weeks, based on the experience of the participating physicians. A clinically significant decrease in the risk of preterm delivery could be 33-50%, and numbers-needed-to-treat (NNT) would be 15-20%, based on analogies to drug treatment evaluations. Thus, the numbers of patients required per group to ensure a level of significance of α = 0.05 (two-tailed) was ascertained, with the power of the test at 1 − β = 0.80. Moreover, considering that 5-10% of patients may withdraw from the study and considering the potential for recruiting patients, a target sample size for each group was determined.
Randomization
Enrolled women were randomly assigned to receive either intravaginal UTI administration or placebo. The randomization sequence was computer generated in balanced block multiples. Randomization factors included maternal and gestational age, parity and severity of cervical shortening as well as history of any previous preterm delivery. For this study, the JOPP research team established and hosted a secure website on the UMIN website that was used to randomize subjects into the conditions. All communication between participating centers and the JOPP research team was encrypted. Staff responsible for recruitment and randomization accessed the website through a password-protected web portal. In this study, six patients were excluded after randomization. The reason for exclusion were patient request (n = 3), lack of follow-up data due to moving after discharge from hospital (n = 2) and treatment that disqualified the patient (n = 1).
All of the enrolled patients were hospitalized (Fig. 1 ). Patients were checked for subclinical infection based on elastase levels in cervical mucus and the presence of bacterial vaginosis. Patients with negative results for subclinical infection were excluded from this study. The patients with subclinical infection were divided into the following two groups: Group A, patients treated with intravaginal UTI administration and Group B, patients who receive placebo.
Intervention and follow-up
All consenting women were inpatients and treated with bed rest. Pregnant women at risk of having a preterm delivery and with a short cervix and subclinical infection or inflammation of the vaginal cervix were randomized into two treatment groups following a double-blinded procedure: Group A, treated by vaginal flushing and administration of UTI and Group B, treated by vaginal flushing and administration of saline (placebo). Warm saline (500 mL) was used for vaginal flushing. Treatment continued up to 31 weeks, 6 days of gestation. The women in all groups were discharged from hospital at 32 weeks of gestation. Outpatient treatment involved bi-or tri-weekly ultrasound evaluation of the lower uterine segment, education regarding the signs and symptoms of preterm labor and routine antenatal care. In the absence of pregnancy complications that required earlier delivery (e.g., premature rupture of membranes, labor, or hemorrhage), the cerclage suture was removed at 37 weeks of gestation. All participants were otherwise treated according to standard obstetric indications, with the route and timing of delivery at the discretion of the attending physician.
Procedures to treat participants under a 'rescue arm' of treatment
When any of the following conditions occurred, the investigators made an appropriate diagnosis based on written procedures and took appropriate medical action. If the condition elevated the risk of preterm delivery, the patient was treated under what was termed a 'rescue arm', with treatment being the same for both groups. a. Antibiotic administration: As mentioned above b. Steroids: As mentioned above. 
Statistical analysis
Categorical variables were analyzed using the ChiSquared test or Mantel-Haenszel test of trends, while continuous variables were compared using the Wilcoxon signed-rank test. Differences between the two groups were assessed using Dunnett's analysis and Tukey's HSD analysis. Differences in the time to birth were assessed by Kaplan-Meier survival curves and the Log-rank test. Analysis was performed using JMP 10.0 (SAS Institute Inc.).
Results
Of the 92 women assessed for eligibility, 70 patients (76.1%) were singleton pregnancies. Of these, 47 patients (51.1%) were allocated to Group A for the administration of UTI, and 45 patients (48.9%) were allocated to Group B (placebo). Three patients in the placebo group left the study. A further four patients in Group A and two in Group B were excluded due to loss of data and reconsidering participation. Overall, 35 patients in Group A and 35 patients in Group B were used for analysis (Fig. 1) . Table 1 shows the demographic characteristics, obstetrics histories and gynecologic histories of the women in Group A and Group B. No significant differences in these characteristics were observed between the two groups. Table 2 shows the clinical characteristics and the pregnancy outcomes of the treatment (UTI) and placebo groups. The mean cervical length, which was an initial criteria for inclusion at the time of randomization, and mean gestational age were comparable between the two groups. There were no statistical differences between the two groups with regard to preterm delivery before 28, 30, 32, 34 and 37 weeks of gestation. Furthermore, there were no significant differences in gestational age at delivery, duration between admission and delivery, babies birth weight, neonatal survival, incidence of compound presentations and the Apgar Score (<7).
There were no significant differences in the proportion continuing pregnancy at each gestational age (weeks) between the two groups (Fig. 2) . Furthermore, no significant differences (P > 0.05) were observed between the treatment and placebo groups with regard to women who remained undelivered after allocation (Fig. 3) .
Discussion
To the best of our knowledge, this is the first report of an RCT for intravaginal UTI administration on pure cervical shortening with vaginosis or cervicitis. The objective of this multicenter, double-blind RCT was to assess the benefits of intravaginal UTI administration in the mid-trimester to prevent preterm birth in women who had a short cervical length and an infection or inflammation in the lower genital tract.
Iams et al. 1 reported higher rates of preterm delivery in patients with a short cervix measured at about 24 weeks of gestation using transvaginal ultrasonography. They found that the increased rate of preterm delivery was associated with an increased severity of cervical shortness. Subsequently, numerous reports have described relationships between cervical length during the second trimester and preterm delivery rates. [2] [3] [4] [5] 10, 39 Recently, cervical shortening has been used as a very sensitive indicator of preterm delivery.
A women's cervix provides protection from vaginal infections ascending into the uterus. A short cervix physically facilitates ascending vaginal or cervical infection or inflammation; thus, it is considered to be a factor contributing to preterm delivery. If inflammation ascends into the cervical canal, cervical maturation progresses, and the pressure maintaining the fetus weakens, resulting in dilation of the cervical os and shortening of the cervix. As a result, inflammation of the cervix is considered a factor in preterm delivery. Topical treatments for bacterial vaginitis and cervicitis have been used to prevent preterm delivery in pregnant women with cervical infection or inflammation and short cervical length. [41] [42] [43] [44] To date, the Japanese government has not approved the use of progesterone supplementation (hydroxyprogesterone caproate) during pregnancy to prevent preterm delivery in Japan, although it has been approved for use in the United States by the Food and Drug Administration (FDA) since 2011. Progesterone has been used to treat women with a history of at least one prior spontaneous preterm delivery. 45 However, alternatives to progesterone needed to be considered in Japan. Topical therapies commonly involve vaginal disinfection and flushing, combined with intravaginal administration of an antibiotic or anti-inflammatory, such as UTI. Differing results have been reported by studies using intravaginal administration of antibiotics. [15] [16] [17] As UTI is safe, both suppositories and vaginal douches are widely used in Japan. 23, [46] [47] [48] Many reports have described the effectiveness of this treatment on advanced threatened preterm delivery, such as for patients with advanced cervical dilation or patients presenting with gestational sac formation. 42, 43 However, none of the reports have assessed the effect of UTI using evidence from a multicenter, double-blind RCT.
In this study, treating pregnant women who had a genital tract inflammation or infection with UTI did not prevent early birth before 37 weeks of gestation, with no statistically significant differences observed between the UTI treatment and placebo group. Furthermore, administering UTI vaginally did not significantly improve the outcomes, which probably resulted from suppression of the inflammatory cytokines like UTI. The effectiveness of UTI in preventing premature labor has been previously reported. 42, 43 Kanayama et al. 20, 23, 49 reported that UTI has a potential to inhibit premature cervical ripening induced by inflammatory cytokines. Furthermore, UTI suppresses the production of inflammatory cytokines involved in spontaneous preterm birth, such as interleukin-1, interleukin-8 and inhibited inflammatory proteins such as neutrophil elastase, plasmin and cathepsin, in the uterine cervix. Based on these results, UTI could be expected to be an effective treatment for preterm delivery due to infections or inflammation. However, in the present study, treatment with UTI showed no statistical significant differences in preterm delivery when compared with the saline placebo. It is possible that saline itself had an effect and suppressed inflammation and infection within the cervix and vagina.
The results of the present study must be considered in light of some limitations. First, the effect of the vaginal douche on patients with infection or inflammation of the lower genital tract could not be examined. Second, as recruiting patients to the study was difficult, the number of participants was low. RCT are not common in Japan, particularly for obstetric studies. Gaining patient acceptance of being allocated to treatment groups through a computer process was difficult. This will require more educational activities to promote the importance of RCT in order to improve the quality of perinatal care in Japan. Third, the preventive effect of progesterone could not be included in the analysis as patients were not treated with progesterone in this study. Fourth, this study did not investigate whether UTI was effective for pregnant women with a shortened cervix, without inflammation or infection. It will be necessary to expand this RCT to increase the number of pregnant women recruited into the study as well as to include pregnant women with a shortened cervix who did not have an inflammation or infection. A larger RCT will improve our understanding of the effectiveness of administering UTI in the prevention of preterm birth, especially because this treatment is already widely used throughout Japan.
In conclusion, transvaginal UTI administration with a vaginal douche for women with a short cervical length < 25 mm between 16 and 26 weeks of gestation and with an infection or inflammation of the lower genital tract may have no benefit in preventing preterm delivery. Future research on the efficacy of UTI treatment should evaluate modified modes of UTI application. Financial support
